13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001534261
Total reported value
$2.0B
$2.0B
38 檔
36.7%
During the Q2 2024 filing period, Casdin Capital, LLC (CIK: 0001534261) submitted its Form 13F report to the U.S. SEC, disclosing a tracked public equity portfolio valued at $2.0B across 38 reported positions.
During Q2 2024, Casdin Capital, LLC's portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | BLFS | Biolife Solutions Inc | Stock-Other | 14.25% | -2.03% | — | |
| 2 | RVMD | Revolution Medicines Inc | Stock-Healthcare | 13.06% | +5.18% | -21.55% | |
| 3 | SRPT | Sarepta Therapeutics Inc | Stock-Healthcare | 12.95% | +0.42% | NEW | |
| 4 | LAB | Standard Biotools Inc | Stock-Other | 8.64% | -2.52% | +3.31% | |
| 5 | WGS | Genedx Holdings CORP | Stock-Other | 7.04% | -1.88% | +12.43% | |
| 6 | RNAGBP | Avidity Biosciences Inc | Stock-Other | 6.50% | — | — | |
| 7 | RLAY | Relay Therapeutics Inc | Stock-Other | 4.21% | +4.16% | +13.81% | |
| 8 | ILMN | Illumina Inc | Stock-Healthcare | 3.83% | -0.29% | +93.55% | |
| 9 | NTLA | Intellia Therapeutics Inc | Stock-Other | 3.42% | -0.04% | +3.90% | |
| 10 | ALNY | Alnylam Pharmaceuticals Inc | Stock-Healthcare | 3.15% | -0.75% | -52.51% | |
| 11 | 2655787D | Blueprint Medicines CORP | Stock-Other | 2.69% | — | — | |
| 12 | DNLI | Denali Therapeutics Inc | Stock-Other | 2.30% | -0.05% | — | |
| 13 | GPCR | Structure Therapeutics Inc | Stock-Other | 2.10% | -1.13% | -37.32% | |
| 14 | EXK | Exact Sciences CORP | Stock-Materials | 2.10% | — | — | |
| 15 | TNYA | Tenaya Therapeutics Inc | Stock-Other | 1.59% | -0.01% | — | |
| 16 | NGNE | Neurogene Inc | Stock-Other | 1.46% | +0.26% | — | |
| 17 | VCYT | Veracyte Inc | Stock-Other | 1.42% | +0.14% | — | |
| 18 | FDMT | 4d Molecular Therapeutics In | Stock-Other | 1.28% | — | — | |
| 19 | BEAM | Beam Therapeutics Inc | Stock-Other | 1.21% | -0.12% | — | |
| 20 | ✓ | Verve Therapeutics Inc | Stock-Other | 1.14% | — | — | |
| 21 | IPSC | Century Therapeutics Inc | Stock-Other | 1.01% | -0.06% | +61.88% | |
| 22 | PLRX | Pliant Therapeutics Inc | Stock-Other | 0.82% | — | — | |
| 23 | TNGX | Tango Therapeutics Inc | Stock-Other | 0.78% | — | — | |
| 24 | TSVT* | 2seventy Bio Inc | Stock-Other | 0.59% | — | — | |
| 25 | CDXS | Codexis Inc | Stock-Other | 0.47% | — | — | |
| 26 | CTNM | Contineum Therapeutics Inc-a | Stock-Other | 0.40% | -0.03% | — | |
| 27 | KYTX | Kyverna Therapeutics Inc | Stock-Other | 0.33% | — | +283.33% | |
| 28 | SNDX | Syndax Pharmaceuticals Inc | Stock-Other | 0.24% | — | — | |
| 29 | ABSI | Absci CORP | Stock-Other | 0.23% | +0.34% | — | |
| 30 | GH | Guardant Health Inc | Stock-Healthcare | 0.22% | -0.81% | — | |
| 31 | PRME | Prime Medicine Inc | Stock-Other | 0.14% | -0.25% | — | |
| 32 | PACB | Pacific Biosciences Of Calif | Stock-Other | 0.11% | -0.01% | — | |
| 33 | GRAL | Grail Inc | Stock-Healthcare | 0.09% | +0.74% | — | |
| 34 | EXAIEUR | Exscientia PLC | Stock-Other | 0.08% | — | — | |
| 35 | GLUE | Monte Rosa Therapeutics Inc | Stock-Other | 0.07% | — | -48.91% | |
| 36 | DNA4EUR | Ginkgo Bioworks Holdings Inc | Stock-Other | 0.04% | — | — | |
| 37 | ✓ | Stock-Other | 0.03% | — | — | ||
| 38 | KRON1USD | Kronos Bio Inc | Stock-Other | 0.01% | — | — |
According to official SEC Form 13F filings, Casdin Capital, LLC reported a total U.S. public equity portfolio value of $2.0B across 38 disclosed positions in Q2 2024.
During Q2 2024, Casdin Capital, LLC's top holdings by market value included BLFS (14.3%)、RVMD (13.1%)、SRPT (12.9%). The largest single position, BLFS, represented 14.3% of total portfolio value.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including BLFS, RVMD, SRPT) accounted for 36.7% of total reported equity market value during Q2 2024.
In Q2 2024, Casdin Capital, LLC made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.